aka Tandutinib is Takeda’s Ph2 FLT3, cKIT, PDGFR inhibitor Blood.
Archive for the ‘Flt3’ Category
AC-220
Posted by kinasepro on March 26, 2009
Is the screening company’s Ph1 FLT-3 compound:
polymorph app: WO/2009/038757
Posted in Ambit, Flt3 | Leave a Comment »
TG-101348
Posted by kinasepro on December 7, 2007
Targegen’s got a press release:
Plans to initiate a multi-center clinical trial of TG101348, an internally discovered, oral, potent, and highly selective JAK2 inhibitor in January, 2008
A poster at ASH:
…Dual-Acting JAK2/FLT3 Small Molecule Kinase Inhibitor for the Treatment of AML
and some pyrimidines in WO/2007/053452:
Posted in biotech, clinical, Flt3, JAK | Leave a Comment »
News of the day
Posted by kinasepro on November 14, 2007
- Ambit grabs 50M in a Series D. Their Lead is AC-220 a ph1 selective Flt3 compound. In WO/2007/109120?
aetiology and limited data in: WO/2005/048953
- Rigel tacks on 3M for the Japanese rights to R-763.
R-788 (Fostamatinib disodium)
Posted by kinasepro on November 9, 2007
R-788 is Rigel’s SYK / Flt3 inhibiting prodrug of R-406, and despite a positive sounding press release on their Ph2 ITP study, the market is reacting negatively so far by knocking 20% off of the stock price.
the name suggests disodium.
Posted in Flt3, Rigel, SYK | 15 Comments »
ABT-869
Posted by kinasepro on June 26, 2007
Phase 2 on the doorstep, Genentech and Abbott just announced a collaboration to include development of the compound w/ backups. No terms disclosed…
Vegf, Flt3, Tie2, c-FMS, Pdgf, c-kit yadda yadda
Posted in Abbott, c-fms, Flt3, Genentech, PDGFR, TIE2, VEGF | Leave a Comment »
ENMD-981693
Posted by kinasepro on June 1, 2007
So Entremed is over in Boston stumping for their Aurora inhibitor and they happened to drop the MW and cLogP:
Only two compounds from WO/2007/041358 fit that bill. That one, and the Z isomer.
Posted in Aurora, biotech, Flt3, multi-target | 4 Comments »
Lestaurtinib
Posted by kinasepro on May 28, 2007
Lestaurtinib / CEP-701 is currently in trials for a handful of indications and first appeared in WO/1988/07045 (US,4,923,986) via Kyowa Hakko Kogyo. The series was first described as a group of PKC inhibitors, but later came this ’98 press release: (emphasis mine)
CEP-701 is one of a series of specific receptor trk kinase inhibitor derived from the indolocarbazole K252a, which was originally synthesized by Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan
Posted in c-Met, Cephalon, Flt3, JAK, Trk, VEGF | 3 Comments »
US20070004763
Posted by kinasepro on January 5, 2007
These are part of a Flt3 and/or TrkB series which JnJ has been putting a beat down on lately.
Posted in Flt3, J&J, Trk | Leave a Comment »
US20060281764
Posted by kinasepro on December 16, 2006
WTF J&J, Oxime-aldehydes? FLT3, TRKb, cKit inhibitors… Shinogi has some related EGF compounds: WO2006106721, and there’s a Biorg Med Chem Lett with the motif in CDK so its not unheard of. Quinazoline isosteres… Cool.
Update >> There’s a couple other relatives that make this a family of applications which all published last Thursday:
This looks like the primary series, and the aniline appears to dial in TRKB – albeit not all that dramatically: US20060281772
US20060281768
Hmm… is LG293 TRKb?
Posted in c-Kit, Flt3, J&J | 2 Comments »